Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia.
Fiche publication
Date publication
mai 2021
Journal
Blood cells, molecules & diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Dr PAGLIUCA Simona
Tous les auteurs :
Awada H, Durmaz A, Gurnari C, Kishtagari A, Zawit M, Pagliuca S, Visconte V
Lien Pubmed
Résumé
Wilms tumor 1 (WT1) gene is commonly mutated in acute myeloid leukemia (AML), particularly in younger age population. The mechanism through which WT1 mutations drive leukemogenesis have not been fully elucidated; however, recent studies reported an association with the epigenetic pathway. Here, we studied the phenotypic characteristics and somatic mutational profile of 114 WT1-mutant AML patients and focused on potential WT1 gene relations to other cooperative genomic events that may impact disease prognosis. Invariant phenotypic and genomic associations of WT1 mutations in AML were uncovered and rigorously described. Our findings help improving the current understanding and definition of WT1-mutant AML patients' characteristics and clinical outcomes.
Mots clés
Acute myeloid leukemia, Clinical associations, WT1 mutations
Référence
Blood Cells Mol Dis. 2021 05;88:102549